Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. France CAR-T Cell Therapy Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Others)
5.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)
5.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)
5.2.4. By Treatment Type (Single Treatment, Combination Treatment)
5.2.5. By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)
5.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
5.2.7. By Region
5.2.8. By Company (2022)
5.3. Market Map
5.3.1. By Product Type
5.3.2. By Tumor Type
5.3.3. By Indication
5.3.4. By Treatment Type
5.3.5. By Targeted Antigen
5.3.6. By End User
5.3.7. By Region
6. Northern France CAR-T Cell Therapy Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Others)
6.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)
6.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)
6.2.4. By Treatment Type (Single Treatment, Combination Treatment)
6.2.5. By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)
6.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
7. Southern France CAR-T Cell Therapy Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Others)
7.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)
7.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)
7.2.4. By Treatment Type (Single Treatment, Combination Treatment)
7.2.5. By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)
7.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
8. Western France CAR-T Cell Therapy Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Others)
8.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)
8.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)
8.2.4. By Treatment Type (Single Treatment, Combination Treatment)
8.2.5. By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)
8.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
9. Central France CAR-T Cell Therapy Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Others)
9.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)
9.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)
9.2.4. By Treatment Type (Single Treatment, Combination Treatment)
9.2.5. By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)
9.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
10. Eastern France CAR-T Cell Therapy Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Others)
10.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)
10.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)
10.2.4. By Treatment Type (Single Treatment, Combination Treatment)
10.2.5. By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)
10.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
11. Southwestern France CAR-T Cell Therapy Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Others)
11.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)
11.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)
11.2.4. By Treatment Type (Single Treatment, Combination Treatment)
11.2.5. By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)
11.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
13.1. Recent Developments
13.2. Mergers & Acquisitions
13.3. Product Launches
14. Policy & Regulatory Landscape
15. Porter’s Five Forces Analysis
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products
16. France Economic Profile
17. Competitive Landscape
17.1. Business Overview
17.2. Product Offerings
17.3. Recent Developments
17.4. Financials (As Reported)
17.5. Key Personnel
17.6. SWOT Analysis
17.6.1. Gilead Sciences, Inc
17.6.2. Novartis International AG
17.6.3. Bristol Myers Squibb Co
17.6.4. Abbvie France, S.L.U.
17.6.5. Cellectis SA
17.6.6. AMGEN S.A.
17.6.7. Pfizer
17.6.8. Merck & Co. Inc
17.6.9. Johnson & Johnson Sant? Beaut? France
17.6.10. Sangamo Therapeutics France
18. Strategic Recommendations